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The eradication of small pox using the mass vaccination 
approach has been the main impetus for our efforts to 
develop a contraceptive vaccine. In fact, long before the 
idea of developing vaccines for prevention of cholera or 
tuberculosis or other infectious diseases was considered, 
efforts were in progress for the development of a 
contraceptive vaccine for controlling the population 
growth, particularly in the developing countries. The 
success of the use of vaccine for small pox, the ease of 
operation, cost effectiveness and long term protection, 
were some of the factors which were the driving forces in 
the efforts to develop contraceptive vaccines. However, 
almost a quarter century after the idea was first con-
sidered, investment of considerable amount of resources 
and efforts of several competent teams, we are no where 
near the actual use of the proposed vaccines. The concept 
of contraceptive vaccines, is radically different from 
conventional vaccines for infectious diseases. Unlike the 
vaccines for infectious diseases such as cholera, tuber-
culosis and small pox wherein no physiological process is 
interfered with, in the immunized subject, the use of 
contraceptive vaccine is intended for interfering with a 
physiological process associated with reproduction in 
normal healthy subjects. In addition, the antigens used are 
the isologous antigens from egg, sperm or certain repro-
ductive hormones. Since these isologous antigens may not 
be as immunogenic as foreign antigens as in the case  
of antigens from organisms that are responsible for 
infectious diseases, maintenance of the antibody titer in 
the immunized subjects over a period is a problem (Herr 
1996). A contraceptive vaccine essentially involves the 
use of a molecule, either a protein or a small ligand which 
has a critical role in the reproductive process. Interfering 
with its function by using antibodies would mean an 
impairment in reproduction. The primary requirement for 
a molecule to be a candidate vaccine is that it should have 
an indispensable specific role in the reproductive process 
and i s absence should not have any adverse effects other 
than impairing fertility. Besides it should be easy and 
economically viable to produce on a large scale. Over the 
years several candidate vaccines have been proposed for 
contraception both in the male and female. 
 Historically, many more efforts have been directed 
towards development of immuno-contraceptives for use in 
th  female because in a traditionally male-dominated 
so iety such as ours, family planning has primarily been 
considered as the woman’s responsibility. In addition, our 
knowledge about the female reproductive system has 
pre ded our understanding about the male reproductive 
system. Also, the sites of interception in the female 
reproductive systems are many more as compared to that 
in the male. Further, in the case of the female, one has to 
deal with only one egg, while in the male, the proposed 
method should be capable of interfering with the 
fertiliz ng ability of thousands of sperms. 
 Over the years, several reproductive hormones have 
been identified as potential targets, both in the male and 
female, such as gonadotropin releasing hormone (GnRH), 
follicle stimulating hormone (FSH), luteimizing hormone 
(LH), human chorin c gonadotropin (hCG) and gonadal 
steroids. In addition, the antigens of trophoblasts and 
early embryo, egg surface antigens and sperm surface 
antigens have also been suggested as possible candidates. 
Of the reproductive hormones, one which has been 
proposed as an immunocontraceptive for both the male 
and female is GnRH the decapeptide produced by the 
ypothalamus, which regulates the synthesis and secretion 
of both FSH and LH, the two important pituitary 
hormones involved in reproduction both in males and in 
females. Administration of antibodies to GnRH resulted in 
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the impairment of fertility both in the male and female 
animal models (Ladd et al 1990; Talwar et al 1993). 
However, neutralization of GnRH also resulted in the 
decrease in libido and functions of other accessory 
reproductive organs in addition to osteoporosis in females 
and loss of body weight in males (due to decrease in the 
level of gonadal steroids). These effects however minor 
they may be, are not acceptable. Efforts are in progress to 
supplement suitable steroids (androgens and estrogens) 
using a variety of delivery systems. However, the precise 
dose of the steroid hormone, which does not have side 
effects (on the prostate by androgen, uterus and mammary 
gland by estrogen) have to be arrived t and we are far 
from the practical application of this approach. 
 Yet another reproductive hormone which has shown 
considerable promise as a candidate vaccine is hCG which 
is indispensable for maintenance of early pregnancy in the 
human female. Both animal and preliminary studies with 
human females have clearly established its efficacy in 
interfering with pregnancy (Talwar et al 1994). However, 
the major problem in application of this approach has 
been the lack of uniform response, which is effective in 
interfering with pregnancy in all the immunized subjects 
and the necessity for use of alternative contraceptives 
until the required titre is obtained. In addition, due to the 
fear of HIV contamination, the use of hCG isolated from 
the urine of human subjects has not been possible and 
until sufficient quantities of recombinant hCG as well as 
methods to elicit uniform and sustained immune response 
in all the subjects become available, the approach is far 
from becoming a reality. Riboflavin carrier protein (RCP) 
is yet another protein which has been demonstrated to 
have an important role in the transport of the important 
vitamin riboflavin in situations wherever a blood/tissue 
barrier operates (e.g. blood/testis: blood/placenta etc.), 
has been suggested as a candidate vaccine for fertility 
control both in males and females (Adiga et al 1997). 
However, considerable work in terms of its mode of 
action, toxicology and clinical trials needs to be done 
before RCP can find its place as a candidate vaccine. 
 Yet another group of antigens, suggested as vaccines 
for immuno contraception in the female are the Zona 
antigens which are the egg surface specific antigens. 
Though animal studies have suggested the possibility of 
using these antigens for immunocontraception, long term 
studies have revealed that injection of Zona antigens 
results in autoimmune oophoritis indicating that immuni-
zation with Zona antigens might induce immunological 
attack on many eggs in the ovary resulting in premature 
ovarian failure (Paterson et al 1992). If this cannot be 
taken care of, it is unlikely that Zona antigens will have 
any place in immuno contraception. 
 In contrast to the number of targets for immuno-
contraception in the female, there are very few potential 
sites of attack in the male. One of the promising 
approaches, is the use of FSH as contraceptive vaccine 
a d several studies using both rodents and monkeys as 
models have established that FSH is indispensable for 
nor al permatogenesis (Moudgal and Sairam 1998). The 
unique advantage of this approach is that neutralization of 
FSH d es not have any effect on serum testosterone levels 
and thus does not affect libido. A phase I clinical trial has 
also been carried out using ovine FSH as an antigen. 
Considering the limited options available for immuno-
contraception for use in the male, the use of FSH appears 
to be promising as a contraceptive vaccine. However, just 
as in the case of hCG, constraints in the availability of 
sufficient quantities of recombinant FSH, methods to 
sustai uniform effective response in all the immunized 
subjects, and the need to use alternative methods of 
ontrac ption until the required titres are reached, are the 
major deterrents for the practical application of this 
method. 
There have also been attempts to employ sperm surface 
antigens as potential candidates for immunocontraception. 
The objective of these efforts is to use sperm-ba ed 
antigens to develop an immunocontraceptive that will 
roduce antibodies in the female reproductive tract to 
block f rtilization by agglutinating or immobilizing 
sperms (Shaha 1999). 
 LDH4 is an isoenzyme of lactate dehydrogenase, a 
glycolytic enzyme that is found only in male germ cells 
and detailed studies have been carried out on its structure 
and function. Studies carried out using baboons have 
revealed only partial efficacy for use as an antifertility 
agent (O’Hearn 1995). Other antigens which are being 
tested in experimental animals, include RSA-1 human 
SP17, Tcle-1, bH20, SP10 (Harrison and Rosenfield 
1996). However, none of the studies have reached a stage 
where it can be inferred that a particular antigen can be 
the candidate for use as a contraceptive vaccines. 
 It is very essential to realize that even after a candidate 
antigen is identified and produced in enough quantities by 
r combinant methods and methods are developed to 
sustain an effective uniform response in 100% of the 
subjects (which is a daunting task), the main drawbacks in 
the application of immunocontraception is the need for 
periodic injections (which will be a major practical 
probl  in a country like ours with a huge rural 
population) and also need for alternate contraceptive 
approaches required until sufficient titres are obtained in 
the subjects. This is all the more so in developing an 
immuno-contraceptives for use in males, since theoreti-
cally, even one sperm is adequate for fertilization and an 
absolute need for 100% efficacy is required. Currently 
efforts are in progress to employ epididymal antigens 
since they are believed to be involved in the process of 
maturation of sperms without which, under normal 
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conditions sperms are incapable of fertilizing the egg 
(Sriraman and Rao 2001). Thus, it i  hoped that by 
interfering with the process of sperm maturation in the 
epididymis, an ideal contraceptive can be developed 
without interfering with the libido. However, even if this 
is achieved, the main problem is the delivery of the specific 
antibody to the epididymis to interfere with the process of 
sperm maturation. One way to overcome the problems of 
lack of uniform response, periodic boosters and need for 
alternative methods until sufficient titre is reached, at least 
in the females is to use high affinity, bio-neutralizing 
humanized orally active recombinant antibodies which can 
be ingested at the appropriate period in the cycle. Although 
this sounds unrealistic, this approach can become a reality 
with the present day technology. 
 Considering all the facts mentioned above, one might 
conclude that immunocontraception has no place in 
fertility control. To quote from a report by the committee 
on contraceptive research and development: “There has 
been much discussion of the desirability of curtailing 
investment in immunocontraception, primarily in response 
to concerns expressed by some women’s groups and by 
individual analysts, that immunocontraception will not 
prove to be a biomedically appropriate contraceptive 
option for women in general and that research and 
development investment in the area would be better 
placed elsewhere”. However, one should realize that 
immunocontraception is an important tool in identifying 
the potential target and the candidate antigens. The app-
roach has the power to provide insights into fundamental 
immunological and physiological structure and mecha-
nism that could enrich development of the applications. 
Following the identification of the candidate molecule 
using the immunological approach, it is the modern 
approach of understanding the molecular basis of inter-
action of the hormone with it receptor, which will provide 
the basis for developing non-protein/non-peptide based 
orally active mimetics to interfere with the action of the 
hormone. Thus, the knowledge gained out of the immuno-
logical approach will be indispensable in developing 
future contraceptives although immunocontracepti  itself 
may not have a place of its own in fertility control 
programme at the moment.  
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